Upstream is pleased to regain access to its laboratories as New Zealand exits the Level 4 and 3 lockdowns that commenced on 25 March.
Upstream regains access to its laboratories following COVID-19 lockdown
From today we expect to have unhindered access to our laboratories so that we may continue to develop Marker A.
Detecting at-risk heart attack patients, a step closer with $2m investment
Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.
Upstream commences testing Marker C on the APACE cohort
The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.